A late-stage clinical trial testing the combination of a Merck cancer treatment and a new type of cancer drug developed by Incyte has failed, dealing a blow to a new drug class that many hoped would expand the reach of cancer immunotherapy.
The Phase 3 study in melanoma tested the FDA-approved Merck (NYSE: MRK) cancer drug pembrolizumab (Keytruda) in combination with epacadostat, which was developed by Wilmington, DE-based Incyte (NASDAQ: INCY). The companies said Friday that an external review of the Phase 3 data concluded that compared to those treated with the Merck drug alone, the combination treatment… Read more »
UNDERWRITERS AND PARTNERS